Homogeneous time-resolved fluorescence (HRTF) has a diversified application capability that includes kinases, GPCR screening and immunoassays
Tecan and CIS Bio have entered into a business partnership to deploy CIS Bio's HTRF technology in Tecan's automation systems for drug discovery and additional life science research applications.
Tecan will license CIS Bio's HTRF technology for use in its high-performance time-resolved fluorescence microplate readers that are used in HTRF-based assays.
HTRF is a leading technology within the drug discovery field and has a diversified application capability that includes kinases, GPCR screening and immunoassays.
HTRF is the first TR-Fret (time-resolved fluorescence resonance energy transfer) technology to be universally applicable for use in this type of screening instrumentation.
Siegfried Sasshofer, product group manager detection for Tecan, said: "CIS Bio has played a major role in the development of technologies within the TR-Fret field and in HTRF/Trace (time-resolved amplified cryptate emission) technologies.
"CIS Bio's proprietary technology, HTRF, is considered the gold standard in the field of homogeneous fluorescence methodologies.
"Our customers can now access this sophisticated technology very easily on our detection systems".
Fran‡ois Degorce, head of HTRF marketing and business development at CIS Bio, added: "We are pleased to establish this partnership with Tecan.
"Our common goal is to enable ready access to our technology and support Tecan's ongoing R and D efforts by helping to develop upgraded solutions for its readers.
"We will also help by supplying reagents for development and certification."
